AbelZeta Inc.

Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is to leverage multinational pharmaceutical companies to facilitate and maximize worldwide patient accessibility. Our goal is to rapidly advance innovative T cell immunotherapies by leveraging proof-of-concept data from early-stage clinical trials. This approach enables informed decision-making promptly, enhancing the overall success of drug development. Clinical data is essential for understanding performance for this new class of cell-based immunotherapies. AbelZeta has endeavored to test drug candidates as fast as possible in investigator-initiated trials in order to de-risk and improve the efficiency of the drug candidate selection process.